Mostrar el registro sencillo del ítem

dc.contributor.authorShoji, Hisashi
dc.contributor.authorVázquez-Sánchez, Daniel A
dc.contributor.authorGonzalez-Diaz, Aida
dc.contributor.authorCubero, Meritxell
dc.contributor.authorTubau, Fe
dc.contributor.authorSantos, Salud
dc.contributor.authorGarcía-Somoza, Dolores
dc.contributor.authorLiñares, Josefina
dc.contributor.authorYuste, Jose Enrique 
dc.contributor.authorMartí, Sara
dc.contributor.authorArdanuy, Carmen
dc.date.accessioned2020-04-27T07:47:56Z
dc.date.available2020-04-27T07:47:56Z
dc.date.issued2018
dc.identifier.citationInfect Drug Resist. 2018 Sep 4;11:1387-1400.es_ES
dc.identifier.issn1178-6973es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/9751
dc.description.abstractBackground: Streptococcus pneumoniae is an important pathogen in chronic obstructive pulmonary disease (COPD). We aimed at showing the recent changes in the epidemiology of pneumococcal diseases in patients with COPD, especially after the introduction of the 13-valent pneumococcal conjugate vaccine (PCV13). Methods: From 2013 to 2016, strains causing invasive pneumococcal disease (IPD), non-bacteremic pneumococcal pneumonia (non-BPP), and acute exacerbation of COPD (AE-COPD) were prospectively included. Antimicrobial susceptibility testing, serotyping, and genotyping were analyzed. Results: We collected 345 pneumococci from 286 COPD patients (57 IPD, 78 non-BPP, and 210 AE-COPD). The most frequent serotypes were serotypes 3 (14.0%), 8 (14.0%), and 12F (8.8%) in IPD; serotypes 3 (16.7%), 11A (9%), 9L/N (7.7%), and 23A (7.7%) in non-BPP; and serotypes 11A (11%), nontypeable (11%), and 6C (10%) in AE-COPD. Resistance rates were highest among AE-COPD strains. Penicillin resistance was associated with serotypes 11A (CC156) and 19A (CC320 and CC230). Compared with previous studies, fluoroquinolone resistance in AE-COPD increased (9.5%), PCV13 serotypes decreased (31.6%, 26.9%, and 16.7% for IPD, non-BPP, and AE-COPD, respectively), and serotype 11A-CC156 in AE-COPD and serotype 8 in IPD increased. Conclusion: The epidemiology of pneumococcal disease in COPD changed after the introduction of PCV13 in children. Increases in the highly invasive serotype 8 among patients with IPD and in serotype 11A-CC156 among patients with AE-COPD could compromise the ability of current PCVs to prevent diseases. Vaccines with a greater coverage could improve the benefits of adult vaccination.es_ES
dc.description.sponsorshipWe thank the staff of Hospital Universitari de Bellvitge for their daily contributions, which made this project possible. This study was supported by grants from Fondo de Investigaciones Sanitarias de la Seguridad Social PI14/00627, PI16/00977, INT 2015/0186, and INT 2016/0177 and from Centro de Investigación Biomédica en Red (CIBER) de Enfermedades Respiratorias (CIBERES CB06/06/0037), an initiative of the Instituto de Salud Carlos III, Madrid, Spain. Financial support was also provided by the European Regional Development Fund. The results have been presented, in part, at the 27th European Congress of Clinical Microbiology and Infectious Diseases, Vienna, Austria, April 22–25, 2017.es_ES
dc.language.isoenges_ES
dc.publisherDove Medical Press es_ES
dc.type.hasVersionVoRes_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/4.0/*
dc.subjectStreptococcus pneumoniaees_ES
dc.subjectChronic obstructive pulmonary diseasees_ES
dc.subjectInvasive pneumococcal diseasees_ES
dc.subjectPneumococcal conjugate vaccinees_ES
dc.titleOverview of pneumococcal serotypes and genotypes causing diseases in patients with chronic obstructive pulmonary disease in a Spanish hospital between 2013 and 2016es_ES
dc.typejournal articlees_ES
dc.rights.licenseAtribución-NoComercial-CompartirIgual 4.0 Internacional*
dc.identifier.pubmedID30214260es_ES
dc.format.volume11es_ES
dc.format.page1387-1400es_ES
dc.identifier.doi10.2147/IDR.S165093es_ES
dc.contributor.funderCentro de Investigación Biomedica en Red - CIBER
dc.contributor.funderUnión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF) 
dc.contributor.funderInstituto de Salud Carlos III 
dc.description.peerreviewedes_ES
dc.relation.publisherversionhttps://doi.org/10.2147/IDR.S165093es_ES
dc.identifier.journalInfection and drug resistancees_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/PI14/00627es_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/ PI16/00977es_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/INT 2015/0186es_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/INT 2016/0177es_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/CIBERES CB06/06/0037es_ES
dc.rights.accessRightsopen accesses_ES


Ficheros en el ítem

Acceso Abierto
Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución-NoComercial-CompartirIgual 4.0 Internacional
Este Item está sujeto a una licencia Creative Commons: Atribución-NoComercial-CompartirIgual 4.0 Internacional